{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:57:50Z","timestamp":1792205870594,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-026-03496-5","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:59:49Z","timestamp":1770879589000},"page":"1408-1422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alpha-1 Antitrypsin Deficiency: Current Landscape of Detection, Management, and Treatment"],"prefix":"10.1007","volume":"43","author":[{"given":"Raunak","family":"Mawani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2562-0295","authenticated-orcid":false,"given":"Anita","family":"Pye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice M.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"6","key":"3496_CR1","doi-asserted-by":"publisher","first-page":"030006052513527","DOI":"10.1177\/03000605251352789","volume":"53","author":"CC Liang","year":"2025","unstructured":"Liang CC, Zhao J, Zhang YQ, Chen J, Wang Y. Research progress on the effect of neutrophil elastase and its inhibitors in respiratory diseases. J Int Med Res. 2025;53(6):03000605251352789.","journal-title":"J Int Med Res"},{"key":"3496_CR2","doi-asserted-by":"publisher","first-page":"175346662513188","DOI":"10.1177\/17534666251318841","volume":"19","author":"AM Turner","year":"2025","unstructured":"Turner AM, Ficker JH, Vianello A, Clarenbach CF, Janciauskiene S, Chorostowska-Wynimko J, et al. Advancing the understanding and treatment of lung pathologies associated with alpha 1 antitrypsin deficiency. Ther Adv Respir Dis. 2025;19:17534666251318840.","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"3496_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40139-017-0147-5","volume":"5","author":"EL Mitchell","year":"2017","unstructured":"Mitchell EL, Khan Z. Liver disease in alpha-1 antitrypsin deficiency: current approaches and future directions. Curr Pathobiol Rep. 2017;5(3):243\u201352.","journal-title":"Curr Pathobiol Rep"},{"issue":"8","key":"3496_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1046\/j.1365-2362.1997.1720717.x","volume":"27","author":"F Callea","year":"1997","unstructured":"Callea F, Gregorini G, Sinico A, Consalez GG, Bossolasco M, Salvidio G, et al. Alpha 1-antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: genetic and clinical implications. Eur J Clin Invest. 1997;27(8):696\u2013702.","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"3496_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bjd.14309","volume":"174","author":"I Blanco","year":"2016","unstructured":"Blanco I, Lipsker D, Lara B, Janciauskiene S. Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: an update. Br J Dermatol. 2016;174(4):753\u201362.","journal-title":"Br J Dermatol"},{"key":"3496_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-16","volume":"3","author":"L Fregonese","year":"2008","unstructured":"Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008;3:16.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3496_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/thorax.2003.006494","volume":"59","author":"M Luisetti","year":"2004","unstructured":"Luisetti M, Seersholm N. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax. 2004;59(2):164\u20139.","journal-title":"Thorax"},{"issue":"2","key":"3496_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF02092300","volume":"90","author":"A Carracedo","year":"1983","unstructured":"Carracedo A, Concheiro L. Distribution of the Pi, TfC, and Gc subtypes in Galicia (North West Spain). Z Rechtsmed. 1983;90(2):153\u20138.","journal-title":"Z Rechtsmed"},{"issue":"5","key":"3496_CR9","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1378\/chest.122.5.1818","volume":"122","author":"FJ de Serres","year":"2002","unstructured":"de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest. 2002;122(5):1818\u201329.","journal-title":"Chest"},{"issue":"7","key":"3496_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.arbres.2023.03.016","volume":"59","author":"I Blanco","year":"2023","unstructured":"Blanco I, Diego I, Casta\u00f1\u00f3n Fern\u00e1ndez C, Bueno P, Miravitlles M. Estimated worldwide prevalence of the PI*ZZ Alpha-1 antitrypsin genotype in subjects with chronic obstructive pulmonary disease. Arch Bronconeumol. 2023;59(7):427\u201334.","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"3496_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MPG.0000000000000196","volume":"58","author":"J Teckman","year":"2014","unstructured":"Teckman J, Pardee E, Howell RR, Mannino D, Sharp RR, Brantly M, et al. Appropriateness of newborn screening for \u03b11-antitrypsin deficiency. J Pediatr Gastroenterol Nutr. 2014;58(2):199\u2013203.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"3496_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/j.1651-2227.1996.tb18230.x","volume":"85","author":"T Thelin","year":"1996","unstructured":"Thelin T, Sveger T, McNeil TF. Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). Acta Paediatr. 1996;85(10):1207\u201312.","journal-title":"Acta Paediatr"},{"key":"3496_CR13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2147\/TCRM.S234377","volume":"16","author":"M Quinn","year":"2020","unstructured":"Quinn M, Ellis P, Pye A, Turner AM. Obstacles to early diagnosis and treatment of Alpha-1 antitrypsin deficiency: current perspectives. Ther Clin Risk Manag. 2020;16:1243\u201355.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"3496_CR14","first-page":"668","volume":"3","author":"RA Sandhaus","year":"2016","unstructured":"Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3(3):668\u201382.","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"135","key":"3496_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1183\/09059180.10010814","volume":"24","author":"NG McElvaney","year":"2015","unstructured":"McElvaney NG. Diagnosing \u03b11-antitrypsin deficiency: how to improve the current algorithm. Eur Respir Rev. 2015;24(135):52\u20137.","journal-title":"Eur Respir Rev"},{"key":"3496_CR16","doi-asserted-by":"publisher","first-page":"204062232110159","DOI":"10.1177\/20406223211015954","volume":"12","author":"KE Foil","year":"2021","unstructured":"Foil KE. Variants of\u00a0SERPINA1\u00a0and the increasing complexity of testing for alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis. 2021;12:20406223211015950.","journal-title":"Ther Adv Chronic Dis"},{"key":"3496_CR17","first-page":"64","volume-title":"\u03b11-Antitrypsin Deficiency (ERS Monograph)","author":"M Barrecheguren","year":"2019","unstructured":"Barrecheguren M, Bals R, Miravitlles M. Clinical approach to diagnosis and assessment. In: Strnad P, Brantly ML, Bals R, editors. \u03b11-Antitrypsin Deficiency (ERS Monograph). Sheffield: European Respiratory Society; 2019. p. 64\u201377."},{"issue":"9","key":"3496_CR18","first-page":"1964","volume":"19","author":"CB Collins","year":"2013","unstructured":"Collins CB, Aherne CM, Ehrentraut SF, Gerich ME, McNamee EN, McManus MC, et al. Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis. Inflamm Bowel Dis. 2013;19(9):1964\u201373.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"3496_CR19","doi-asserted-by":"publisher","first-page":"1700610","DOI":"10.1183\/13993003.00610-2017","volume":"50","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in \u03b11-antitrypsin deficiency. Eur Respir J. 2017;50(5):1700610.","journal-title":"Eur Respir J"},{"issue":"3","key":"3496_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1164\/rccm.201108-1428CI","volume":"185","author":"JK Stoller","year":"2012","unstructured":"Stoller JK, Aboussouan LS. A Review of a1-Antitrypsin Deficiency. Am J Respir Crit Care Med. 2012;185(3):246\u201359.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3496_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society; European Respiratory Society","year":"2002","unstructured":"American Thoracic Society; European Respiratory Society. American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277\u2013304.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3496_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1055\/s-0030-1254068","volume":"31","author":"GR Washko","year":"2010","unstructured":"Washko GR. Diagnostic imaging in COPD. Semin Respir Crit Care Med. 2010;31(3):276\u201385.","journal-title":"Semin Respir Crit Care Med"},{"key":"3496_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.rmed.2017.05.011","volume":"129","author":"S F\u00e4hndrich","year":"2017","unstructured":"F\u00e4hndrich S, Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, et al. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency. Respir Med. 2017;129:8\u201315.","journal-title":"Respir Med"},{"issue":"1","key":"3496_CR24","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/S2213-2600(24)00413-2","volume":"13","author":"P Venkatesan","year":"2025","unstructured":"Venkatesan P. GOLD COPD report: 2025 update. Lancet Respir Med. 2025;13(1):e7\u20138.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"3496_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000481867","volume":"95","author":"EV Low","year":"2018","unstructured":"Low EV, Hughes SM, Zaffarullah S, Kantas D, Stockley RA, Turner AM. ICS Use May Modify FEV1 Decline in \u03b11-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils. Respiration. 2018;95(2):114\u201321.","journal-title":"Respiration"},{"issue":"1","key":"3496_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000119718","volume":"76","author":"L Corda","year":"2008","unstructured":"Corda L, Bertella E, La Piana GE, Boni E, Redolfi S, Tantucci C. Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD. Respiration. 2008;76(1):61\u20138.","journal-title":"Respiration"},{"key":"3496_CR27","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2023-3-1","volume":"12","author":"PH Feitosa","year":"2023","unstructured":"Feitosa PH. Diagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potential. Drugs Context. 2023;12:2023-3-1.","journal-title":"Drugs Context"},{"issue":"8","key":"3496_CR28","volume":"8","author":"A Lenferink","year":"2017","unstructured":"Lenferink A, Brusse-Keizer M, van der Valk PD, Frith PA, Zwerink M, Monninkhof EM, et al. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;8(8):CD011682.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3496_CR29","first-page":"429","volume":"17","author":"RA Sandhaus","year":"2020","unstructured":"Sandhaus RA, Turino G, Brantly M, et al. Improving the lives of patients with alpha-1 antitrypsin deficiency. COPD. 2020;17(5):429\u201337.","journal-title":"COPD"},{"issue":"1","key":"3496_CR30","first-page":"121","volume":"11","author":"FA Alwadani","year":"2024","unstructured":"Alwadani FA, Wheeler K, Pittaway H, Turner AM. Pulmonary rehabilitation for chronic obstructive pulmonary disease patients with underlying alpha-1 antitrypsin deficiency: a systematic review and practical recommendations. Chronic Obstr Pulm Dis. 2024;11(1):121\u201332.","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"1","key":"3496_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/thorax-2025-223273","volume":"81","author":"F Alwadani","year":"2025","unstructured":"Alwadani F, Ellis PR, Newnham M, et al. Pulmonary rehabilitation and quality of life in alpha-1 antitrypsin deficiency: findings from a retrospective cohort study. Thorax. 2025;81(1):78\u201380.","journal-title":"Thorax"},{"issue":"8","key":"3496_CR32","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.rmed.2014.05.001","volume":"108","author":"TJ Ringbaek","year":"2014","unstructured":"Ringbaek TJ, Seersholm N, Perch M, Iversen M, Lange P. Prognosis of patents with alpha-1 antitrypsin deficiency on long-term oxygen therapy. Respir Med. 2014;108(8):1189\u201394.","journal-title":"Respir Med"},{"key":"3496_CR33","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.2147\/COPD.S148509","volume":"12","author":"M Ekstr\u00f6m","year":"2017","unstructured":"Ekstr\u00f6m M, Tanash H. Lung transplantation and survival outcomes in patients with oxygen dependent COPD with regard to their alpha-1 antitrypsin deficiency status. Int J Chron Obstruct Pulmon Dis. 2017;12:3281\u20137.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"3496_CR34","first-page":"100","volume":"6","author":"ML Brantly","year":"2018","unstructured":"Brantly ML, Lascano JE, Shahmohammadi A. Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence. Chronic Obstr Pulm Dis. 2018;6(1):100\u201314.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"3496_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2147\/COPD.S149429","volume":"13","author":"KR Chapman","year":"2018","unstructured":"Chapman KR, Chorostowska-Wynimko J, Koczulla AR, Ferrarotti I, McElvaney NG. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. Int J Chron Obstruct Pulmon Dis. 2018;13:419\u201332.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3496_CR36","doi-asserted-by":"publisher","first-page":"175346662412719","DOI":"10.1177\/17534666241271917","volume":"18","author":"C Aljama","year":"2024","unstructured":"Aljama C, Martin T, Granados G, Miravitlles M, Barrecheguren M. Personalised indication of augmentation therapy for emphysema associated with severe alpha-1 antitrypsin deficiency: a case series. Ther Adv Respir Dis. 2024;18:17534666241271916.","journal-title":"Ther Adv Respir Dis"},{"issue":"12","key":"3496_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.067710","volume":"61","author":"J Stolk","year":"2006","unstructured":"Stolk J. Alpha-1-antitrypsin augmentation treatment: does one size fit all? Thorax. 2006;61(12):1034.","journal-title":"Thorax"},{"issue":"2","key":"3496_CR38","doi-asserted-by":"publisher","first-page":"2101410","DOI":"10.1183\/13993003.01410-2021","volume":"59","author":"AN Franciosi","year":"2022","unstructured":"Franciosi AN, Fraughen D, Carroll TP, McElvaney NG. Alpha-1 Antitrypsin Deficiency: clarifying the role of the putative protective threshold. Eur Respir J. 2022;59(2):2101410.","journal-title":"Eur Respir J"},{"key":"3496_CR39","doi-asserted-by":"publisher","first-page":"204062232110101","DOI":"10.1177\/20406223211010172","volume":"12","author":"I Barjaktarevic","year":"2021","unstructured":"Barjaktarevic I, Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Ther Adv Chronic Dis. 2021;12:20406223211010172.","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"3496_CR40","first-page":"53","volume":"9","author":"P Hernandez","year":"2025","unstructured":"Hernandez P, Boss\u00e9 Y, Bush P, Chapman KR, Maltais F, Penz ED, et al. Alpha-1-antitrypsin deficiency targeted testing and augmentation therapy: a\u00a0Canadian Thoracic Society meta-analysis and clinical practice guideline. Can J Respir Crit Care Sleep Med. 2025;9(2):53\u201369.","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"9991","key":"3496_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","volume":"386","author":"KR Chapman","year":"2015","unstructured":"Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, et al. Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360\u20138.","journal-title":"Lancet"},{"issue":"1","key":"3496_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-2600(16)30430-1","volume":"5","author":"NG McElvaney","year":"2017","unstructured":"McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, et al. Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017;5(1):51\u201360.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"3496_CR43","first-page":"109","volume":"12","author":"ESY Ho","year":"2025","unstructured":"Ho ESY, Ellis PR, Kavanagh D, Subramanian D, Stockley RA, Turner AM. Proposal and validation of the minimum clinically important difference in emphysema progression. Chronic Obstr Pulm Dis. 2025;12(2):109\u201316.","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"suppl 63","key":"3496_CR44","first-page":"PA3383","volume":"54","author":"P Ellis","year":"2019","unstructured":"Ellis P, Holm K, Choate R, Mannino D, Stockley R, Sandhaus R, et al. Comparison of outcomes in augmentation na\u00efve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Eur Respir J. 2019;54(suppl 63):PA3383.","journal-title":"Eur Respir J"},{"issue":"2","key":"3496_CR45","first-page":"139","volume":"10","author":"PR Ellis","year":"2023","unstructured":"Ellis PR, Holm KE, Choate R, Mannino DM, Stockley RA, Sandhaus RA, et al. Quality of life and mortality outcomes for augmentation na\u00efve and augmented patients with severe alpha-1 antitrypsin deficiency. Chron Obstruct Pulm Dis J COPD Found. 2023;10(2):139\u201347.","journal-title":"Chron Obstruct Pulm Dis J COPD Found"},{"issue":"9","key":"3496_CR46","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1164\/rccm.202305-0863OC","volume":"208","author":"DD Fraughen","year":"2023","unstructured":"Fraughen DD, Ghosh AJ, Hobbs BD, Funk GC, Meischl T, Clarenbach CF, et al. Augmentation therapy for severe Alpha-1 antitrypsin deficiency improves survival and is decoupled from spirometric decline-a multinational registry analysis. Am J Respir Crit Care Med. 2023;208(9):964\u201374.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3496_CR47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.rmed.2015.01.022","volume":"109","author":"S Sorrells","year":"2015","unstructured":"Sorrells S, Camprubi S, Griffin R, Chen J, Ayguasanosa J. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency. Respir Med. 2015;109(4):490\u20139.","journal-title":"Respir Med"},{"issue":"21","key":"3496_CR48","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa030287","volume":"348","author":"A Fishman","year":"2003","unstructured":"Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059\u201373.","journal-title":"N Engl J Med."},{"issue":"1","key":"3496_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.athoracsur.2006.07.080","volume":"83","author":"JK Stoller","year":"2007","unstructured":"Stoller JK, Gildea TR, Ries AL, Meli YM, Karafa MT, National Emphysema Treatment Trial Research Group. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg. 2007;83(1):241\u201351.","journal-title":"Ann Thorac Surg"},{"key":"3496_CR50","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2147\/COPD.S130440","volume":"12","author":"RG Edgar","year":"2017","unstructured":"Edgar RG, Patel M, Bayliss S, Crossley D, Sapey E, Turner AM. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. Int J Chron Obstruct Pulmon Dis. 2017;12:1295\u2013308.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"3496_CR51","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.chest.2020.12.007","volume":"159","author":"K Klooster","year":"2021","unstructured":"Klooster K, Slebos DJ. Endobronchial valves for the treatment of advanced emphysema. Chest. 2021;159(5):1833\u201342.","journal-title":"Chest"},{"issue":"24","key":"3496_CR52","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa1507807","volume":"373","author":"K Klooster","year":"2015","unstructured":"Klooster K, ten Hacken NH, Hartman JE, Kerstjens HA, van Rikxoort EM, Slebos DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med. 2015;373(24):2325\u201335.","journal-title":"N Engl J Med"},{"key":"3496_CR53","doi-asserted-by":"publisher","DOI":"10.21037\/jovs.2017.10.04","volume":"3","author":"A Fiorelli","year":"2017","unstructured":"Fiorelli A, Santoriello C, De Felice A, Ferrigno F, Carlucci A, De Ruberto E, et al. Bronchoscopic lung volume reduction with endobronchial valves for heterogeneous emphysema: long-term results. J Vis Surg. 2017;3:170.","journal-title":"J Vis Surg"},{"issue":"13","key":"3496_CR54","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa0900928","volume":"363","author":"FC Sciurba","year":"2010","unstructured":"Sciurba FC, Ernst A, Herth FJ, Strange C, Criner GJ, Marquette CH, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010;363(13):1233\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"3496_CR55","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000528182","volume":"102","author":"S Everaerts","year":"2023","unstructured":"Everaerts S, Hartman JE, Van Dijk M, Koster TD, Slebos DJ, Klooster K. Bronchoscopic lung volume reduction in patients with emphysema due to Alpha-1 antitrypsin deficiency. Respiration. 2023;102(2):134\u201342.","journal-title":"Respiration"},{"issue":"2","key":"3496_CR56","first-page":"87","volume":"5","author":"N Marchetti","year":"2018","unstructured":"Marchetti N, Kaufman T, Chandra D, Herth FJ, Shah PL, Slebos DJ, et al. Endobronchial coils versus lung volume reduction surgery or medical therapy for treatment of advanced homogenous emphysema. Chronic Obstr Pulm Dis. 2018;5(2):87\u201396.","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"20","key":"3496_CR57","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/jama.2016.6261","volume":"315","author":"FC Sciurba","year":"2016","unstructured":"Sciurba FC, Criner GJ, Strange C, Shah PL, Michaud G, Connolly TA, et al. Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema: the RENEW Randomized Clinical Trial. JAMA. 2016;315(20):2178\u201389.","journal-title":"JAMA"},{"issue":"13","key":"3496_CR58","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.2147\/COPD.S176366","volume":"5","author":"JM Perotin","year":"2018","unstructured":"Perotin JM, Leroy S, Marquette CH, Mal H, Dutau H, Bourdin A, et al. Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2018;5(13):3645\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"3496_CR59","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000365662","volume":"88","author":"G Hillerdal","year":"2014","unstructured":"Hillerdal G, Mindus S. One- to four-year follow-up of endobronchial lung volume reduction in alpha-1-antitrypsin deficiency patients: a case series. Respiration. 2014;88(4):320\u20138.","journal-title":"Respiration"},{"key":"3496_CR60","doi-asserted-by":"publisher","first-page":"204062232110029","DOI":"10.1177\/20406223211002988","volume":"12","author":"MR Zamora","year":"2021","unstructured":"Zamora MR, Ataya A. Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis. 2021;12:20406223211002988.","journal-title":"Ther Adv Chronic Dis"},{"issue":"8","key":"3496_CR61","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.arbres.2014.08.003","volume":"51","author":"D Giacoboni","year":"2015","unstructured":"Giacoboni D, Barrecheguren M, Esquinas C, Rodr\u00edguez E, Berastegui C, L\u00f3pez-Meseguer M, et al. Characteristics of candidates for lung transplantation due to chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency emphysema. Arch Bronconeumol. 2015;51(8):379\u201383.","journal-title":"Arch Bronconeumol"},{"issue":"12","key":"3496_CR62","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.healun.2011.07.003","volume":"30","author":"HA Tanash","year":"2011","unstructured":"Tanash HA, Riise GC, Hansson L, Nilsson PM, Piitulainen E. Survival benefit of lung transplantation in individuals with severe \u03b11-anti-trypsin deficiency (PiZZ) and emphysema. J Heart Lung Transplant. 2011;30(12):1342\u20137.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"3496_CR63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/icvts\/ivw078","volume":"23","author":"M Fakhro","year":"2016","unstructured":"Fakhro M, Ingemansson R, Skog I, Algotsson L, Hansson L, Koul B, et al. 25-year follow-up after lung transplantation at Lund University Hospital in Sweden: superior results obtained for patients with cystic fibrosis. Interact Cardiovasc Thorac Surg. 2016;23(1):65\u201373.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"11","key":"3496_CR64","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.healun.2005.03.001","volume":"24","author":"CM Burton","year":"2005","unstructured":"Burton CM, Milman N, Carlsen J, Arendrup H, Eliasen K, Andersen CB, et al. The Copenhagen National Lung Transplant Group: survival after single lung, double lung, and heart-lung transplantation. J Heart Lung Transplant. 2005;24(11):1834\u201343.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"3496_CR65","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/tri.13038","volume":"31","author":"BC Gulack","year":"2018","unstructured":"Gulack BC, Mulvihill MS, Ganapathi AM, Speicher PJ, Chery G, Snyder LD, et al. Survival after lung transplantation in recipients with alpha-1-antitrypsin deficiency compared to other forms of chronic obstructive pulmonary disease: a national cohort study. Transpl Int. 2018;31(1):45\u201355.","journal-title":"Transpl Int"},{"issue":"2","key":"3496_CR66","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/15412555.2015.1048850","volume":"13","author":"HM Stone","year":"2016","unstructured":"Stone HM, Edgar RG, Thompson RD, Stockley RA. Lung transplantation in alpha-1-antitrypsin deficiency. COPD. 2016;13(2):146\u201352.","journal-title":"COPD"},{"issue":"10","key":"3496_CR67","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1164\/rccm.200511-1797PP","volume":"173","author":"DA Lomas","year":"2006","unstructured":"Lomas DA. The selective advantage of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2006;173(10):1072\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3496_CR68","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cld.2022.03.004","volume":"26","author":"A Suri","year":"2022","unstructured":"Suri A, Patel D, Teckman JH. Alpha-1 antitrypsin deficiency liver disease. Clin Liver Dis. 2022;26(3):391\u2013402.","journal-title":"Clin Liver Dis"},{"key":"3496_CR69","first-page":"100287","volume":"19","author":"L Marzi","year":"2025","unstructured":"Marzi L, Ferrarotti I, Benini F, Mega A, Luisa S. Alpha-1 antitrypsin deficiency-associated liver disease A review focusing on new assessment tools and therapies. J Liver Trans. 2025;19:100287.","journal-title":"J Liver Trans"},{"key":"3496_CR70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.12.012","author":"R Loomba","year":"2026","unstructured":"Loomba R, Clark VC, Mandorfer M, Miravitlles M, Brantly M, Karpen SJ, et al. Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATD-LD). Gastroenterology. 2026. https:\/\/doi.org\/10.1053\/j.gastro.2025.12.012.","journal-title":"Gastroenterology"},{"issue":"3","key":"3496_CR71","first-page":"272","volume":"7","author":"OS Usmani","year":"2020","unstructured":"Usmani OS. Feasibility of aerosolized alpha-1 antitrypsin as a therapeutic option. Chronic Obstr Pulm Dis. 2020;7(3):272\u20139.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"3496_CR72","unstructured":"Ots. \u201cRNA Single-Base Editing Therapy That Treats Genetic Lung and Liver Disease Entered Clinical Trials.\u201d Oligonucleotide Therapeutics Society, 2025."},{"issue":"3","key":"3496_CR73","first-page":"282","volume":"11","author":"ML Brantly","year":"2024","unstructured":"Brantly ML, Kuhn BT, Farah HW, Mahadeva R, Cole A, Chang CL, et al. Recombinant alpha-1 antitrypsin-Fc fusion protein INBRX-101 in adults with alpha-1 antitrypsin deficiency: a phase 1 study. Chron Obstruct Pulm Dis. 2024;11(3):282\u201392.","journal-title":"Chron Obstruct Pulm Dis"},{"key":"3496_CR74","unstructured":"\u201cPress Release: Sanofi\u2019s Efdoralprin Alfa Met All Primary and Key Secondary Endpoints in Alpha-1 Antitrypsin Deficiency Emphysema Phase 2 Study.\u201d Sanofi, www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-10-22-05-00-00-3170787. Accessed 8 Nov 2025."},{"issue":"5","key":"3496_CR75","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000699","volume":"9","author":"M Fromme","year":"2025","unstructured":"Fromme M, Klebingat F, Ellis P, Strnad P. Alpha-1 antitrypsin deficiency-associated liver disease: from understudied disorder to the poster child of genetic medicine. Hepatol Commun. 2025;9(5):e0699.","journal-title":"Hepatol Commun"},{"key":"3496_CR76","unstructured":"Wave Life Sciences. Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency. Date last accessed: 20 May 2025. Date last updated: 6 December 2023."},{"key":"3496_CR77","unstructured":"Beam Therapeutics. Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1\/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation. Date last accessed: 20 May 2025. Date last updated: 10 March 2025."},{"key":"3496_CR78","doi-asserted-by":"publisher","first-page":"2501019","DOI":"10.1183\/13993003.01019-2025","volume":"66","author":"JM Wells","year":"2025","unstructured":"Wells JM, Titlestad IL, Tanash H, Turner AM, Chapman KR, et al. Two randomized controlled Phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency. Eur Respir J. 2025;66:2501019.","journal-title":"Eur Respir J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03496-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03496-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03496-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:02:09Z","timestamp":1775728929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03496-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3496"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03496-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Raunak Mawani and Anita Pye have nothing to disclose. Alice Turner has received grants or honoraria from AstraZeneca, GlaxoSmithKline, CSL Behring, Takeda, Vertex, Sanofi, Beam, AiRNA, Korrobio, Tessera, and Grifols Biotherapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This review article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}